|
1
|
Yuan E: Taiwan area: Death rate of ten
leading sites of malignant neoplasms. Taiwan: Department of Health,
Executive Yuan; pp. 160–173. 2006
|
|
2
|
Terry MB, Gaudet MM and Gammon MD: The
epidemiology of gastric cancer. Semin Radiat Oncol. 12:111–127.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ushijima T and Sasako M: Focus on gastric
cancer. Cancer Cell. 5:121–125. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
González CA, Sala N and Capellá G: Genetic
susceptibility and gastric cancer risk. Int J Cancer. 100:249–260.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zheng L, Wang L, Ajani J and Xie K:
Molecular basis of gastric cancer development and progression.
Gastric Cancer. 7:61–77. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Smith MG, Hold GL, Tahara E and El-Omar
EM: Cellular and molecular aspects of gastric cancer. 12:2979–2990.
2006.
|
|
7
|
El-Rifai W and Powell SM: Molecular
biology of gastric cancer. Semin Radiat Oncology. 12:128–140. 2002.
View Article : Google Scholar
|
|
8
|
Watson SA, Grabowska AM, El-Zaatari M and
Takhar A: Gastrin-active participant or bystander in gastric
carcinogenesis? Nat Rev Cancer. 6:936–946. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Resende C, Ristimäki A and Machado JC:
Genetic and epigenetic alteration in gastric carcinogenesis.
Helicobacter. 15(Suppl 1): S34–S39. 2010. View Article : Google Scholar
|
|
10
|
Nakajima M, Sawada H, Yamada Y, Watanabe
A, Tatsumi M, Yamashita J, Matsuda M, Sakaguchi T, Hirao T and
Nakano H: The prognostic significance of amplification and
overexpression of c-MET and c-erb B-2 in human gastric carcinomas.
Cancer. 85:1894–1902. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chen CT, Kim H, Liska D, Gao S,
Christensen JG and Weiser MR: MET activation mediates resistance to
lapatinib inhibition of HER2-amplified gastric cancer cells. Mol
Cancer Ther. 11:660–669. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Park DI, Yun JW, Park JH, Oh SJ, Kim HJ,
Cho YK, Sohn CI, Jeon WK, Kim BI, Yoo CH, et al: HER-2/neu
amplification is an independent prognostic factor in gastric
cancer. Dig Dis Sci. 51:1371–1379. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhang XL, Yang YS, Xu DP, Qu JH, Guo MZ,
Gong Y and Huang J: Comparative study on overexpression of HER2/neu
and HER3 in gastric cancer. World J Surg. 33:2112–2118. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
De Vita F, Giuliani F, Silvestris N,
Catalano G, Ciardiello F and Orditura M: Human epidermal growth
factor receptor 2 (HER2) in gastric cancer: A new therapeutic
target. Cancer Treat Rev. 36(Suppl 3): S11–S15. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Geyer CE, Forster J, Lindquist D, Chan S,
Romieu CG, Pienkowski T, Jagiello-Gruszfeld A, Crown J, Chan A,
Kaufman B, et al: Lapatinib plus capecitabine for HER2-positive
advanced breast cancer. N Engl J Med. 355:2733–2743. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hierro C, Rodon J and Tabernero J:
Fibroblast growth factor (FGF) receptor/FGF inhibitors: Novel
targets and strategies for optimization of response of solid
tumors. Semin Oncol. 42:801–819. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Deng N, Goh LK, Wang H, Das K, Tao J, Tan
IB, Zhang S, Lee M, Wu J, Lim KH, et al: A comprehensive survey of
genomic alterations in gastric cancer reveals systematic patterns
of molecular exclusivity and co-occurrence among distinct
therapeutic targets. Gut. 61:673–684. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Huang T, Wang L, Liu D, Li P, Xiong H,
Zhuang L, Sun L, Yuan X and Qiu H: FGF7/FGFR2 signal promotes
invasion and migration in human gastric cancer through upregulation
of thrombospondin-1. Int J Oncol. 50:1501–1512. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kim HP, Han SW, Song SH, Jeong EG, Lee MY,
Hwang D, Im SA, Bang YJ and Kim TY: Testican-1-mediated
epithelial-mesenchymal transition signaling confers acquired
resistance to lapatinib in HER2-positive gastric cancer. Oncogene.
33:3334–3341. 2014. View Article : Google Scholar
|
|
20
|
Edge SB and Compton CC: The American Joint
Committee on Cancer: The 7th edition of the AJCC cancer staging
manual and the future of TNM. Ann Surg Oncol. 17:1471–1474. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Liao XH, Lu DL, Wang N, Liu LY, Wang Y, Li
YQ, Yan TB, Sun XG, Hu P and Zhang TC: Estrogen receptor α mediates
proliferation of breast cancer MCF-7 cells via a
p21/PCNA/E2F1-dependent pathway. FEBS J. 281:927–942. 2014.
View Article : Google Scholar
|
|
22
|
Ghosh RD, Ghuwalewala S, Das P, Mandloi S,
Alam SK, Chakraborty J, Sarkar S, Chakrabarti S, Panda CK and
Roychoudhury S: MicroRNA profiling of cisplatin-resistant oral
squamous cell carcinoma cell lines enriched with
cancer-stem-cell-like and epithelial-mesenchymal transition-type
features. Sci Rep. 6:239322016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2−ΔΔCT method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
24
|
Lu DL, Sookthai D, Le Cornet C, Katzke VA,
Johnson TS, Kaaks R and Fortner RT: Reproducibility of serum
oxysterols and lanosterol among postmenopausal women: Results from
EPIC-Heidelberg. Clin Biochem. 52:117–122. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zöller M: CD44: Can a cancer-initiating
cell profit from an abundantly expressed molecule? Nat Rev Cancer.
11:254–267. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yoshikawa K, Noguchi K, Nakano Y, Yamamura
M, Takaoka K, Hashimoto-Tamaoki T and Kishimoto H: The Hippo
pathway transcriptional co-activator, YAP, confers resistance to
cisplatin in human oral squamous cell carcinoma. Int J Oncol.
46:2364–2370. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lee RC, Feinbaum RL and Ambros V: The C.
elegans heter-ochronic gene lin-4 encodes small RNAs with antisense
complementarity to lin-14. Cell. 75:843–854. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Pasquinelli AE, Reinhart BJ, Slack F,
Martindale MQ, Kuroda MI, Maller B, Hayward DC, Ball EE, Degnan B,
Müller P, et al: Conservation of the sequence and temporal
expression of let-7 heterochronic regulatory RNA. Nature.
408:86–89. 2000. View
Article : Google Scholar : PubMed/NCBI
|
|
29
|
Luqmani YA, Graham M and Coombes RC:
Expression of basic fibroblast growth factor, FGFR1 and FGFR2 in
normal and malignant human breast, and comparison with other normal
tissues. Br J Cancer. 66:2731992. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Nagatsuma AK, Aizawa M, Kuwata T, Doi T,
Ohtsu A, Fujii H and Ochiai A: Expression profiles of HER2, EGFR,
MET and FGFR2 in a large cohort of patients with gastric
adenocarcinoma. Gastric Cancer. 18:227–238. 2015. View Article : Google Scholar
|
|
31
|
Wesche J, Haglund K and Haugsten EM:
Fibroblast growth factors and their receptors in cancer. Biochem J.
437:199–213. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Park J, Kim SY, Kim HJ, Kim KM, Choi EY
and Kang MS: A reciprocal regulatory circuit between CD44 and FGFR2
via c-myc controls gastric cancer cell growth. Oncotarget.
7:28670–28683. 2016.PubMed/NCBI
|
|
33
|
Moriyama T, Ohuchida K, Mizumoto K, Cui L,
Ikenaga N, Sato N and Tanaka M: Enhanced cell migration and
invasion of CD133+ pancreatic cancer cells cocultured
with pancreatic stromal cells. Cancer. 116:3357–3368. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Fang XJ, Jiang H, Zhu YQ, Zhang LY, Fan QH
and Tian Y: Doxorubicin induces drug resistance and expression of
the novel CD44st via NF-κB in human breast cancer MCF-7 cells.
Oncol Rep. 31:2735–2742. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Kinugasa Y, Matsui T and Takakura N: CD44
expressed on cancer-associated fibroblasts is a functional molecule
supporting the stemness and drug resistance of malignant cancer
cells in the tumor microenvironment. Stem Cells. 32:145–156. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
He W, Li Y, Chen X, Lu L, Tang B, Wang Z,
Pan Y, Cai S, He Y and Ke Z: miR-494 acts as an anti-oncogene in
gastric carcinoma by targeting c-myc. J Gastroenterol Hepatol.
29:1427–1434. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Zhao XQ, Liang TJ and Fu JW: miR-494
inhibits invasion and proliferation of gastric cancer by targeting
IGF-1R. Eur Rev Med Pharmacol Sci. 20:3818–3824. 2016.PubMed/NCBI
|
